SG11202013248YA - Pharmaceutical formulations of masked antibodies - Google Patents
Pharmaceutical formulations of masked antibodiesInfo
- Publication number
- SG11202013248YA SG11202013248YA SG11202013248YA SG11202013248YA SG11202013248YA SG 11202013248Y A SG11202013248Y A SG 11202013248YA SG 11202013248Y A SG11202013248Y A SG 11202013248YA SG 11202013248Y A SG11202013248Y A SG 11202013248YA SG 11202013248Y A SG11202013248Y A SG 11202013248YA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical formulations
- masked antibodies
- masked
- antibodies
- formulations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712906P | 2018-07-31 | 2018-07-31 | |
PCT/US2019/044197 WO2020028401A1 (fr) | 2018-07-31 | 2019-07-30 | Formulations pharmaceutiques d'anticorps masqués |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202013248YA true SG11202013248YA (en) | 2021-02-25 |
Family
ID=67766250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202013248YA SG11202013248YA (en) | 2018-07-31 | 2019-07-30 | Pharmaceutical formulations of masked antibodies |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210236636A1 (fr) |
EP (2) | EP4218821A3 (fr) |
JP (2) | JP7412409B2 (fr) |
KR (1) | KR20210039395A (fr) |
CN (1) | CN112533639A (fr) |
AR (1) | AR117628A1 (fr) |
AU (1) | AU2019314355A1 (fr) |
BR (1) | BR112021001616A2 (fr) |
CA (1) | CA3105751A1 (fr) |
CL (2) | CL2021000224A1 (fr) |
EA (1) | EA202190382A1 (fr) |
IL (1) | IL279622A (fr) |
MA (1) | MA53333A (fr) |
MX (1) | MX2021001085A (fr) |
SG (1) | SG11202013248YA (fr) |
TW (1) | TW202019466A (fr) |
WO (1) | WO2020028401A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023518518A (ja) * | 2020-03-23 | 2023-05-01 | ザイムワークス ビーシー インコーポレイテッド | マスクされたil12融合タンパク質及びその使用方法 |
WO2023070353A1 (fr) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anticorps anti-cd47 et leurs procédés d'utilisation |
WO2023222580A1 (fr) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Nouveaux anticorps masqués |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
AU2007240732B2 (en) * | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
EP3492488A1 (fr) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci |
EP3543256A1 (fr) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Compositions d anticorps modifiées et leurs procédés de production et d'utilisation |
SG10201912670XA (en) * | 2010-05-14 | 2020-02-27 | Amgen Inc | High concentration antibody formulations |
JP2015521625A (ja) | 2012-06-22 | 2015-07-30 | シトムクス セラピューティクス,インコーポレイティド | 抗−Jagged1/Jagged2交差反応性抗体、活性化可能抗−Jagged抗体及びそれらの使用方法 |
CA2913732A1 (fr) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions et procedes permettant de conjuguer des anticorps activables |
WO2015013671A1 (fr) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Anticorps multispécifiques, anticorps activables multispécifiques et leurs méthodes d'utilisation |
WO2015066279A2 (fr) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Anticorps activables se liant au récepteur du facteur de croissance épidermique et méthodes d'utilisation de ceux-ci |
EP3172235A2 (fr) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps |
TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
AU2016315656A1 (en) | 2015-08-28 | 2018-02-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
EP3397281B1 (fr) * | 2015-12-29 | 2020-09-09 | Outlook Therapeutics, Inc. | Formulations tamponnées de bévacizumab |
MX2019006624A (es) * | 2016-12-09 | 2019-08-01 | Seattle Genetics Inc | Anticuerpos bivalentes enmascarados por helices superenrolladas. |
JOP20190189A1 (ar) * | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
EP3749363A1 (fr) * | 2018-02-08 | 2020-12-16 | Amgen Inc. | Formulation d'anticorps pharmaceutique à ph faible |
-
2019
- 2019-07-30 JP JP2021504838A patent/JP7412409B2/ja active Active
- 2019-07-30 CN CN201980050417.XA patent/CN112533639A/zh active Pending
- 2019-07-30 KR KR1020217004765A patent/KR20210039395A/ko unknown
- 2019-07-30 WO PCT/US2019/044197 patent/WO2020028401A1/fr unknown
- 2019-07-30 AU AU2019314355A patent/AU2019314355A1/en active Pending
- 2019-07-30 MX MX2021001085A patent/MX2021001085A/es unknown
- 2019-07-30 EP EP23153918.0A patent/EP4218821A3/fr active Pending
- 2019-07-30 TW TW108127091A patent/TW202019466A/zh unknown
- 2019-07-30 CA CA3105751A patent/CA3105751A1/fr active Pending
- 2019-07-30 SG SG11202013248YA patent/SG11202013248YA/en unknown
- 2019-07-30 EA EA202190382A patent/EA202190382A1/ru unknown
- 2019-07-30 BR BR112021001616-3A patent/BR112021001616A2/pt unknown
- 2019-07-30 US US17/262,962 patent/US20210236636A1/en active Pending
- 2019-07-30 AR ARP190102156A patent/AR117628A1/es unknown
- 2019-07-30 MA MA053333A patent/MA53333A/fr unknown
- 2019-07-30 EP EP19759082.1A patent/EP3829642A1/fr not_active Withdrawn
-
2020
- 2020-12-21 IL IL279622A patent/IL279622A/en unknown
-
2021
- 2021-01-28 CL CL2021000224A patent/CL2021000224A1/es unknown
-
2023
- 2023-09-21 CL CL2023002797A patent/CL2023002797A1/es unknown
- 2023-12-26 JP JP2023219159A patent/JP2024038115A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA53333A (fr) | 2021-11-03 |
KR20210039395A (ko) | 2021-04-09 |
IL279622A (en) | 2021-03-01 |
TW202019466A (zh) | 2020-06-01 |
EA202190382A1 (ru) | 2021-05-17 |
JP7412409B2 (ja) | 2024-01-12 |
AR117628A1 (es) | 2021-08-18 |
MX2021001085A (es) | 2021-03-31 |
CL2021000224A1 (es) | 2021-06-11 |
EP4218821A3 (fr) | 2023-12-06 |
AU2019314355A1 (en) | 2021-01-28 |
CL2023002797A1 (es) | 2024-03-08 |
EP3829642A1 (fr) | 2021-06-09 |
EP4218821A2 (fr) | 2023-08-02 |
JP2021532156A (ja) | 2021-11-25 |
BR112021001616A2 (pt) | 2021-05-04 |
JP2024038115A (ja) | 2024-03-19 |
US20210236636A1 (en) | 2021-08-05 |
CA3105751A1 (fr) | 2020-02-06 |
WO2020028401A1 (fr) | 2020-02-06 |
CN112533639A (zh) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279464A (en) | Pharmaceutical formulation of odevixibat | |
ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201807942D0 (en) | Pharmaceutical formulation | |
IL279622A (en) | Pharmaceutical formulations of masked antibodies | |
IL275639A (en) | Formulation for RNA administration | |
EP3399996A4 (fr) | Procédés d'administration d'hepcidine | |
IL278151A (en) | Formulations of human anti-pd-l1 antibodies | |
ZA202006264B (en) | Stable formulations of therapeutic antibody | |
ZA202006570B (en) | Pharmaceutical formulations | |
EP3432925A4 (fr) | Administration d'un anticorps monoclonal anti-lgr5 | |
ZA201708434B (en) | Formulations for small intestinal delivery of rsv and norovirus antigens | |
ZA202102871B (en) | Pharmaceutical formulation | |
IL272773A (en) | Pharmaceutical preparations containing anti-amyloid cell antibodies | |
IL280596A (en) | Anti-IL-1 antibody in a cell, its pharmaceutical preparation and its use | |
IL278927A (en) | pharmaceutical preparation | |
IL276311A (en) | Methyllactam ring compound and its pharmaceutical use | |
IL267279A (en) | Pharmaceutical formulations of suvorexant | |
IL280642A (en) | A method for preparing a pharmaceutical formulation for an antibody | |
ZA202006346B (en) | Pharmaceutical preparation | |
SG11202010792TA (en) | Improved pharmaceutical formulations | |
EP3463296A4 (fr) | Formulations pharmaceutiques de nitrite et leurs utilisations | |
GB2569615B (en) | An oral liquid pharmaceutical composition of lamotrigine | |
GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies |